Lexeo Therapeutics (LXEO) Amortizatization of Intangibles (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Amortizatization of Intangibles of $42000.0 for Q1 2026, down 47.5% sequentially from $80000.0 in Q4 2025, and down 47.5% YoY from $80000.0 in Q1 2025.
Powered by 
Analysis
Lexeo Therapeutics (LXEO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Amortizatization of Intangibles for 5 years, with the latest figure at $42000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 47.5% year-over-year to $42000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $282000.0 (up 1466.67% YoY) and the FY2025 annual result came in at $320000.0, up 1291.3% from the prior year.
- Amortizatization of Intangibles declined to $42000.0 in Q1 2026 per LXEO's latest filing, from $80000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $90000.0 in Q4 2022 and troughed at -$222000.0 in Q4 2024.
- A 5-year average of $55133.3 and a median of $80000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles tumbled 381.01% in 2024, then surged 136.04% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $90000.0 in 2022, then declined by 12.22% to $79000.0 in 2023, then sank by 381.01% to -$222000.0 in 2024, then surged by 136.04% to $80000.0 in 2025, then tumbled by 47.5% to $42000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $42000.0, $80000.0, and $80000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Lexeo Therapeutics | 419.14 Mn | 419.14 Mn | - | 80,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80,000.00 |
| Mar 31, 2026 | 393,000.00 |
| Dec 31, 2025 | 385,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Dec 31, 2024 | 366,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 322,000.00 |
| Dec 31, 2023 | 334,000.00 |
| Sep 30, 2023 | 79,000.00 |
| Jun 30, 2023 | 79,000.00 |
| Mar 31, 2023 | 321,000.00 |
| Dec 31, 2022 | 297,000.00 |
| Sep 30, 2022 | 46,000.00 |